Patheon

In a recent interview, pharma industry expert Sam Bejaoui, director of portfolio services at Thermo Fisher Scientific, showcased the advantages of #oralsoliddosage (#OSD) forms, such as: - Ease of administration - Greater patient convenience - More accurate dosing Additionally, he noted that #OSD forms generally provide a longer, more stable #shelflife compared to other types of treatments, while also highlighting some of their potential drawbacks. To explore our end-to-end #OSD capabilities, including our network of state-of-the-art #CDMO facilities, Click here: http://spr.ly/6043q7HQd

Thermo Fisher Scientific is getting ready for #BioEurope2024 in #Stockholm! Visit our subject-matter experts (#SMEs) at booth #100 to explore our comprehensive #CDMO and #CRO capabilities for #largemolecule drugs, including #biologics. With over 30 years of experience in the #biologics space and having worked on hundreds of #biologics programs for our #biotech and #pharma partners, we’re ready to help advance your innovations and transform treatment landscapes. Want a deeper dive into our end-to-end #drugdevelopment offerings? Schedule a private 1:1 meeting with one of our SMEs here: http://spr.ly/6048qfmTp

Thermo Fisher Scientific is proud to support the #ISCT2025 #InnovationZone, a platform for disruptive #cell and #genetherapy start-ups to showcase their groundbreaking #technologies in the #drugdevelopment field.   As an #advancedtherapy #CDMO partner, we help our customers drive innovation and accelerate access to new treatments through our extensive technical expertise, end-to-end services, and robust global supply network.   We look forward to connecting at #ISCT2025 in #NewOrleans from May 7-10, 2025, to discuss how we can advance your next #innovation. Learn more here: https://lnkd.in/gESqX6_A  

In a recent interview, #pharma industry expert Anil Kane, Ph.D., MBA, executive director and global head of technical and scientific affairs at Thermo Fisher Scientific, discussed why #oralsoliddose (#OSD) forms are here to stay. Anil noted that even #largemolecules, such as #peptides and #proteins, are being evaluated for their potential in #oraldrugdelivery—a novel approach that can lead to improved treatment adherence and outcomes. Watch the video clip to learn more.

Developing a new #cell and #genetherapy can cost billions of dollars—yes, billions—a staggering amount that is unfortunately out of reach for many of today’s #drugdevelopers aiming to advance #personalizedmedicine. Indeed, the high costs associated with #cell and #genetherapy development remain a significant hurdle for #biotech and #pharma companies, potentially preventing groundbreaking treatments from reaching patients in need. This challenge was a key focus of Kelly Howard ’s session at #CPHIMilan2024, where she highlighted how the right financial strategy can make all the difference. During her presentation, Kelly emphasized that Thermo Fisher Scientific’s in-house Financial Solutions team is available to help #biotech, #pharma, and #academic organizations navigate these high costs with confidence. If you missed Kelly’s session, you can read the full recap here: http://spr.ly/6047q0dOt

Today’s #biotech and #pharma sponsors are facing rising costs, increased competition, and pressure to innovate faster than ever. To stay ahead, maximizing value at every stage of #drugdevelopment is critical—from early-stage research to #clinicaltrials and #commercialization. Join Thermo Fisher Scientific for an upcoming webinar where we’ll share findings from the Tufts Center for the Study of Drug Development on how integrating end-to-end #CDMO and #CRO services and solutions can significantly boost your program's #expectedNetPresentValue (eNPV). In this webinar, you'll learn: • The benefits of leveraging #eNPV modeling for combined #CDMO and #CRO services • How to streamline processes with #ThermoFisher’s Accelerator™ Drug Development • Real-world case studies showcasing successes from #biotech and #pharma sponsors Led by Dr. Joseph DiMasi from Tufts University, as well as Brenda Bruker and Brittany Hall from Thermo Fisher Scientific, this is a can’t-miss event. RSVP by clicking below: http://spr.ly/6046qxNbm

Thermo Fisher Scientific is proud to introduce our latest innovation: The #tamperevidentcarton, designed to help ensure the security of the #pharmaceuticalsupplychain. Patented in 2024, this cutting-edge packaging solution combines a protective carton design with tamper-evident sealing to ensure your #clinicaltrial materials are safe. To learn about the benefits of our #tamperevidentcarton, including how its design avoids the common risk of traditional label seals lifting at frozen temperatures, watch our overview video. Additional information is available here: http://spr.ly/6045qQVgv

#CPHIMilan2024 was a success! Thank you to everyone who visited our Thermo Fisher Scientific booth and joined the conversation in our #ExpertCafe. Special thanks to those who attended Jennifer Cannon's session on accelerating drug development through strategic #CDMO and #CRO partnerships. In the session, Jennifer explained how integrating #CDMO and #CRO services can speed up timelines, reduce costs, and meet the unique needs of therapies across modalities. Key takeaways included: - The advantages of comprehensive, end-to-end #CDMO/#CRO partnerships - Real-world insights from #biotech and #pharma customer case studies - Preliminary findings from a Tufts Center for the Study of Drug Development Jennifer also introduced our Accelerator™ Drug Development, 360° CDMO and CRO services, officially launched at #CPHIMilan2024. Read the recap by clicking below: http://spr.ly/6048qQ8HG

Thanks to everyone who attended the #FestivalofBiologics2024 and visited Thermo Fisher Scientific's booth. It was great to connect with you and discuss our #drugdevelopment capabilities. Our speaker session, “The critical role of the 5,000 L bioreactor: Bridging drug substance supply needs between early and late-stage development,” was packed, with standing room only. A special thanks to Erica Byerley and Julia Braunmueller for exploring the complexities of successfully scaling up #biologic products with efficient and flexible #manufacturingtechnologies. As a fully integrated #CDMO/#CRO, Thermo Fisher Scientific is committed to helping #biotech and #pharma companies move from molecule to medicine to market with seamless execution. To explore our #largemolecule #development and #manufacturing capabilities in detail, click here: http://spr.ly/6049qtKVP

#Autologouscelltherapies, which harness a patient’s own cells to treat various conditions, represent a groundbreaking approach in #personalizedmedicine. However, since each #autologoustherapy is a bespoke product—precisely tailored to the individual patient—the manufacturing process is highly complex. Our new blog, “Manufacturing autologous cell therapies: Challenges and best practices,” explores these complexities and provides practical solutions, including: - Optimizing #supplychain management at every step - Addressing #scalability challenges with advanced solutions - Maintaining compliance with #regulatoryrequirements It also highlights how a #CDMO partner like Thermo Fisher Scientific can help #drugdevelopers reduce costs and expedite the delivery of these life-changing treatments. Read the blog here: http://spr.ly/6042qsMQj